公开(公告)号：US20240352429A1

公开(公告)日：2024-10-24

申请号：US18623379

申请日：2024-04-01

申请人： KANEKA CORPORATION

发明人： Koki Sasamoto ,  Takahide Sasaki ,  Hirofumi Maeda ,  Mitsuaki Kitano

IPC分类号： C12N7/00 ,  C12N5/00 ,  C12N15/86

CPC分类号： C12N7/00 ,  C12N5/0018 ,  C12N15/86 ,  C12N2500/62 ,  C12N2501/999 ,  C12N2750/14143 ,  C12N2750/14152

摘要： Described is an agent for inducing viral vector production which includes a cell growth inhibitor A. The cell growth inhibitor A includes a compound which inhibits progression of the cell cycle in G2 phase or M phase. Additionally, a method of producing a viral vector and a method of inducing viral vector production using the same are described. The methods include introducing a nucleic acid into a cell and adding the cell growth inhibitor A to the cell between 6 hours before and 6 hours after the time of introducing the nucleic acid.

公开(公告)号：US12104168B2

公开(公告)日：2024-10-01

申请号：US17054108

申请日：2019-05-10

申请人： Agency For Science, Technology And Research

发明人： Iwona Szczerbinska ,  Yun Shen Chan ,  Huck Hui Ng

IPC分类号： C12N5/00 ,  C12N5/071

CPC分类号： C12N5/0018 ,  C12N5/0672 ,  C12N5/0678 ,  C12N5/068 ,  C12N2501/01 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/12 ,  C12N2501/13 ,  C12N2501/135 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/727

摘要： The present invention relates to a cell culture medium for preparing liver, gastric, pancreatic, colon or intestinal adult stem cell isolated from adult tissue, as well as for maintaining such stem cell in the undifferentiated state. The cell culture medium comprises a base medium; an ABL and SRC dual kinase inhibitor/an ABL kinase inhibitor and a SRC kinase inhibitor; a mitogenic factor; a WNT signalling pathway activator; a stimulator for NAD+ and NADP+ generation; and a cAMP/PKA pathway activator. In a particular embodiment, the ABL and SRC dual kinase inhibitor is Dasatinib; the mitogenic factor is EGF; the WNT signalling pathway activator is R-Spondin 1; the stimulator for NAD+ and NADP+ generation is nicotinamide; and the cAMP/PKA pathway activator is cholera endotoxin.

公开(公告)号：US20240317835A1

公开(公告)日：2024-09-26

申请号：US18733576

申请日：2024-06-04

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Andrew Tustian ,  Ankit Vartak ,  Thomas Daly ,  Erica Pyles ,  Nisha Palackal ,  Shunhai Wang ,  Ning Li

IPC分类号： C07K14/71 ,  A61K38/18 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/28 ,  C12N5/00 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/02 ,  G01N30/80

CPC分类号： C07K14/71 ,  A61K38/1866 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/283 ,  C12N5/0018 ,  C12N5/0031 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  C07K2317/622 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2800/10 ,  G01N2030/027

摘要： The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

公开(公告)号：US20240301092A1

公开(公告)日：2024-09-12

申请号：US18575016

申请日：2022-06-29

申请人： TEGA Therapeutics, Inc.

发明人： Bryan E. THACKER ,  Jeffrey D. ESKO ,  Charles A. GLASS

IPC分类号： C08B37/00 ,  A61K31/727 ,  C08L5/10 ,  C12N5/00 ,  C12N5/0787 ,  C12N9/10

CPC分类号： C08B37/0075 ,  A61K31/727 ,  C08L5/10 ,  C12N5/0018 ,  C12N5/0642 ,  C12N9/13 ,  C12N2500/34 ,  C12N2510/02 ,  C12N2511/00

摘要： Provided herein are methods of producing heparin and heparan sulfate from modified cells, such as modified MST cells, and compositions comprising heparin and heparan sulfate isolated from modified cells.

公开(公告)号：US20240299282A1

公开(公告)日：2024-09-12

申请号：US18139825

申请日：2023-04-26

申请人： AiVita Biomedical, Inc.

发明人： Gabriel NISTOR

IPC分类号： A61K8/73 ,  A61K8/64 ,  A61K9/00 ,  A61K9/08 ,  A61K38/17 ,  A61K38/18 ,  A61K47/26 ,  A61K47/40 ,  A61K47/54 ,  A61K47/61 ,  A61K47/69 ,  A61Q7/00 ,  C07K14/47 ,  C12N5/00 ,  C12N5/0735 ,  C12N5/074

CPC分类号： A61K8/738 ,  A61K8/64 ,  A61K9/0014 ,  A61K9/08 ,  A61K38/1709 ,  A61K38/18 ,  A61K47/26 ,  A61K47/40 ,  A61K47/543 ,  A61K47/61 ,  A61K47/6951 ,  A61Q7/00 ,  C07K14/4705 ,  C12N5/0018 ,  C12N5/0606 ,  C12N5/0607 ,  A61K2800/56 ,  C12N2500/34

摘要： Disclosed herein are compositions comprising complexes of cyclodextrins and lipid-modified stem cell proteins. Also disclosed are topical compositions the complexes. Methods of using the compositions for the therapeutic purposes are also disclosed as well as methods of producing the compositions.

公开(公告)号：US12071634B2

公开(公告)日：2024-08-27

申请号：US17337978

申请日：2021-06-03

申请人： The USA, as represented by the Secretary, Department of Health and Human Services

发明人： Manfred Boehm ,  Guibin Chen ,  Mahendra Rao ,  Andre Larochelle

IPC分类号： C12N5/074 ,  C12N5/00 ,  C12N5/077 ,  C12N5/0775 ,  C12N5/0789

CPC分类号： C12N5/0607 ,  C12N5/0018 ,  C12N5/0647 ,  C12N5/0661 ,  C12N5/0662 ,  C12N5/0696 ,  C12N2500/05 ,  C12N2500/30 ,  C12N2500/36 ,  C12N2500/42 ,  C12N2500/44 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/26 ,  C12N2506/03 ,  C12N2506/45

摘要： Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derided cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.

公开(公告)号：US20240279604A1

公开(公告)日：2024-08-22

申请号：US18582703

申请日：2024-02-21

申请人： Industry-University Cooperation Foundation Hanyang University Erica Campus

发明人： Chong Suk RYOU ,  Hyun Jung PARK

IPC分类号： C12N5/0793 ,  C12M1/00 ,  C12N5/00 ,  C12N5/079

CPC分类号： C12N5/0619 ,  C12M23/02 ,  C12N5/0018 ,  C12N5/0622 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2501/115 ,  C12N2503/02 ,  C12N2506/08 ,  C12N2513/00

摘要： The present invention relates to a method for producing a spheroid including neurons and astrocytes, the method including: culturing induced pluripotent stem cell-neural progenitor cells (iPSC-NPCs) in an NPC medium; culturing the cultured cells in a neuronal differentiation medium (NDM); and culturing the cultured cells in a glial differentiation medium (GDM). The spheroid produced by the method according to the present invention contains mature neurons and astrocytes which express a desired marker after 3 weeks of in vitro culture and has a uniform size, and thus can be used for simple visual screening to confirm drug efficacy.

公开(公告)号：US12054612B2

公开(公告)日：2024-08-06

申请号：US17561133

申请日：2021-12-23

申请人： Industrial Technology Research Institute

发明人： Yun-Chung Teng ,  Jen-Huang Huang ,  Ying-Wen Shen ,  Yu-Bing Liou ,  Hsin-Yi Hsu ,  Li-Hsin Lin ,  Yuchi Wang ,  Hsin-Hsin Shen

IPC分类号： C08L89/06 ,  A61L27/26 ,  A61L27/52 ,  B33Y80/00 ,  C08J3/24 ,  C12N5/00

CPC分类号： C08L89/06 ,  A61L27/26 ,  A61L27/52 ,  B33Y80/00 ,  C08J3/24 ,  C12N5/0018 ,  C08J2389/06 ,  C08J2489/06 ,  C08L2203/02 ,  C08L2205/02 ,  C08L2205/16 ,  C08L2312/00 ,  C12N2500/34

摘要： A bioprintable material is provided. The bioprintable material includes a hydrogel and microfilaments mixed in the hydrogel. The hydrogel includes a first collagen. The microfilament includes a second collagen. The diameter of the microfilament is ranging from 5 microns to 200 microns. The weight ratio of the microfilaments to the first collagen is ranging from 0.01:1 to 10:1.

公开(公告)号：US12049489B2

公开(公告)日：2024-07-30

申请号：US18340707

申请日：2023-06-23

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Andrew Tustian ,  Ankit Vartak ,  Thomas Daly ,  Erica Pyles ,  Nisha Palackal ,  Shunhai Wang ,  Ning Li

IPC分类号： C07K1/36 ,  A61K38/18 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K14/71 ,  C07K16/22 ,  C07K16/28 ,  C12N5/00 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  G01N30/02

CPC分类号： C07K14/71 ,  A61K38/1866 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/283 ,  C12N5/0018 ,  C12N5/0031 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  C07K2317/622 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2800/10 ,  G01N2030/027

摘要： The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.

公开(公告)号：US12043845B2

公开(公告)日：2024-07-23

申请号：US16620091

申请日：2018-06-08

申请人： Polpharma Biologics S.A.

发明人： Louis Boon ,  Lenneke De Winter ,  Tomasz Sitar

IPC分类号： C12N5/00 ,  C12N15/67

CPC分类号： C12N5/0018 ,  C12N15/67 ,  C12N2500/32 ,  C12N2500/34

摘要： The invention provide a method for reducing the amount of acidic species and/or increasing the amount of basic species in a composition comprising a recombinant protein or for increasing the specific production rate of mammalian cells expressing a recombinant protein to simplify subsequent clarification and purification of the recombinant protein, said method comprising culturing mammalian cells expressing said recombinant protein in a cell culture medium comprising citrulline.